BLA 761126 · Tanvex Biopharma USA INC
Nypozi
Filgrastim-Txid · Injection · Leukocyte Growth Factor
OrphanLast checked: Nov 20, 2026Latest source record: Jun 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jun 28, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,650
302 Phase 3, 127 recruiting
FAERS reports
55
55 serious, 39 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 15, 2026.
NYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NYPOZI is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NYPOZI is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of...
Mechanism: Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes‚ fibroblasts, and endothelial cells. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation‚ differentiation, and selected end-cell functions (including enhanced phagocytic ability‚ priming of the cellular metabolism...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- NYPOZI · FILGRASTIM-TXID 300MCG/0.5ML · INJECTABLE, INJECTION · Prescription
- NYPOZI · FILGRASTIM-TXID 480MCG/0.8ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Filgrastim" as an intervention, any sponsor and status, largest first.
- Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated DonorsPivotal-lookingRecruiting
Center for International Blood and Marrow Transplant ResearchResearch network
NCT00785525 · 60,000 participants (planned) · Start Feb 1997 · Primary completion Jan 2030
Drug: Filgrastim · For: Healthy
Sites: Boca Raton, Florida; Rockville, Maryland; Minneapolis, Minnesota · 4 sites in all
- Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial InfarctionPivotal-lookingStatus unknown
Recardio, Inc.Industry
NCT05881382 · 4,100 participants (planned) · Start Sep 2023 · Primary completion Sep 2025
Drug: Dutogliptin + Filgrastim; Placebo · For: ST Elevation Myocardial Infarction
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)Pivotal-lookingCompleted
University Hospital MuensterAcademic, hospital or other
NCT00266136 · 3,500 participants · Start Jun 1999 · Primary completion Jan 2007
Drug: Cytarabine; Thioguanine and 3 more · For: Acute Myeloid Leukemia
Sites: Münster, Germany
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast CancerPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT00070564 · 3,294 participants · Start Nov 2003 · Primary completion Jan 2015
Drug: pegfilgrastim; AC regimen and 3 more · For: Breast Cancer
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 542 sites in all
- Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney CancerPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00002611 · 3,031 participants · Start Jul 1995 · Primary completion Jun 2002
Drug: dactinomycin; filgrastim and 4 more · For: Kidney Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 235 sites in all
- A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerPivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03498716 · 2,199 participants · Start Aug 2, 2018 · Primary completion Aug 14, 2023
Drug: Atezolizumab; Paclitaxel and 2 more · For: Triple Negative Breast Cancer
Sites: Concord, California; Los Angeles, California; St. Helena, California · 364 sites in all
- Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00014222 · 2,104 participants · Start Dec 4, 2000 · Primary completion Feb 10, 2014
Drug: epoetin alfa; filgrastim and 5 more · For: Breast Cancer
Sites: Fort Smith, Arkansas; Little Rock, Arkansas; La Jolla, California · 78 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- adverse event27
- death20
- febrile neutropenia8
- off label use1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 5 |
| 2025 | 10 |
| 2026 | 40 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Smith TJ, Bohlke K, Lyman GH, et al. · J Clin Oncol 2015 · Practice Guideline, Research Support, Non-U.S. Gov't
- Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, et al. · J Clin Oncol 2003 · Clinical Trial, Multicenter Study
- Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
Womer RB, West DC, Krailo MD, et al. · J Clin Oncol 2012 · Multicenter Study, Randomized Controlled Trial
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS, Bohlius J, Cameron DA, et al. · Eur J Cancer 2011 · Consensus Statement, Practice Guideline
- A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
Dale DC, Crawford J, Klippel Z, et al. · Support Care Cancer 2018 · Meta-Analysis, Systematic Review
- Same-day pegfilgrastim and chemotherapy.
Lokich J · Cancer Invest 2005 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Tanvex Biopharma USA INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.